Clinical practice in the use of adjuvant chemotherapy for patients with colon cancer in South Korea

A multi-center, prospective, observational study

Jung Han Kim, Moo Jun Baek, Byung Kwon Ahn, Dae Dong Kim, Ikyong Kim, Jin Soo Kim, Byung Noe Bae, Bong Gun Seo, Sang Hun Jung, Kwan Hee Hong, Hungdai Kim, Dong Guk Park, Ji Hye Lee

Research output: Contribution to journalArticle

Abstract

Background: Adjuvant chemotherapy is a crucial part of treatment for patients with locally advanced colon cancer. This study was conducted to investigate the actual practice in the use of adjuvant chemotherapy for patients with high-risk stage II or stage III colon cancer in South Korea. Methods: This was a 24-month open-label, prospective, observational study conducted at 12 centers across South Korea. Patients with high-risk stage II and stage III colon cancer receiving adjuvant chemotherapy after curative surgery were included, and data were collected at baseline, third, and sixth month. Results: A total of 246 patients were included in the analyses. Of five available regimens (FOLFOX, CAPOX, 5-FU/LV, capecitabine, and UFT/LV), FOLFOX was most commonly used (82.5%). Investigators indicated the "efficacy" as the major cause for selecting FOLFOX or CAPOX. For 5-FU/LV, capecitabine, or UFT/LV, the "safety" or "patient's characteristics (age, comorbidity, and stage)" was one of the most important selecting factors. Patients receiving 5-FU/LV, capecitabine, or UFT/LV had older age, worse PS and lower disease stage (stage II) than patients receiving FOLFOX or CAPOX. Hematologic toxicities were the most common cause of dose adjustment and treatment delay. Conclusions: In South Korea, FOLFOX was the most commonly used regimen for adjuvant chemotherapy and its efficacy was the main cause for selecting this regimen. Patients receiving 5-FU/LV, capecitabine, or UFT/LV had older age, worse PS and lower disease stage (stage II) than patients receiving FOLFOX or CAPOX.

Original languageEnglish
Pages (from-to)136-143.pdf
JournalJournal of Cancer
Volume7
Issue number2
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Republic of Korea
Adjuvant Chemotherapy
Colonic Neoplasms
Observational Studies
Prospective Studies
Fluorouracil
Patient Safety
Comorbidity
Research Personnel
Capecitabine
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Kim, Jung Han ; Baek, Moo Jun ; Ahn, Byung Kwon ; Kim, Dae Dong ; Kim, Ikyong ; Kim, Jin Soo ; Bae, Byung Noe ; Seo, Bong Gun ; Jung, Sang Hun ; Hong, Kwan Hee ; Kim, Hungdai ; Park, Dong Guk ; Lee, Ji Hye. / Clinical practice in the use of adjuvant chemotherapy for patients with colon cancer in South Korea : A multi-center, prospective, observational study. In: Journal of Cancer. 2016 ; Vol. 7, No. 2. pp. 136-143.pdf.
@article{847b8b12b376447cb2da265a804a3ab9,
title = "Clinical practice in the use of adjuvant chemotherapy for patients with colon cancer in South Korea: A multi-center, prospective, observational study",
abstract = "Background: Adjuvant chemotherapy is a crucial part of treatment for patients with locally advanced colon cancer. This study was conducted to investigate the actual practice in the use of adjuvant chemotherapy for patients with high-risk stage II or stage III colon cancer in South Korea. Methods: This was a 24-month open-label, prospective, observational study conducted at 12 centers across South Korea. Patients with high-risk stage II and stage III colon cancer receiving adjuvant chemotherapy after curative surgery were included, and data were collected at baseline, third, and sixth month. Results: A total of 246 patients were included in the analyses. Of five available regimens (FOLFOX, CAPOX, 5-FU/LV, capecitabine, and UFT/LV), FOLFOX was most commonly used (82.5{\%}). Investigators indicated the {"}efficacy{"} as the major cause for selecting FOLFOX or CAPOX. For 5-FU/LV, capecitabine, or UFT/LV, the {"}safety{"} or {"}patient's characteristics (age, comorbidity, and stage){"} was one of the most important selecting factors. Patients receiving 5-FU/LV, capecitabine, or UFT/LV had older age, worse PS and lower disease stage (stage II) than patients receiving FOLFOX or CAPOX. Hematologic toxicities were the most common cause of dose adjustment and treatment delay. Conclusions: In South Korea, FOLFOX was the most commonly used regimen for adjuvant chemotherapy and its efficacy was the main cause for selecting this regimen. Patients receiving 5-FU/LV, capecitabine, or UFT/LV had older age, worse PS and lower disease stage (stage II) than patients receiving FOLFOX or CAPOX.",
author = "Kim, {Jung Han} and Baek, {Moo Jun} and Ahn, {Byung Kwon} and Kim, {Dae Dong} and Ikyong Kim and Kim, {Jin Soo} and Bae, {Byung Noe} and Seo, {Bong Gun} and Jung, {Sang Hun} and Hong, {Kwan Hee} and Hungdai Kim and Park, {Dong Guk} and Lee, {Ji Hye}",
year = "2016",
month = "1",
day = "1",
doi = "10.7150/jca.13405",
language = "English",
volume = "7",
pages = "136--143.pdf",
journal = "Journal of Cancer",
issn = "1837-9664",
publisher = "Ivyspring International Publisher",
number = "2",

}

Kim, JH, Baek, MJ, Ahn, BK, Kim, DD, Kim, I, Kim, JS, Bae, BN, Seo, BG, Jung, SH, Hong, KH, Kim, H, Park, DG & Lee, JH 2016, 'Clinical practice in the use of adjuvant chemotherapy for patients with colon cancer in South Korea: A multi-center, prospective, observational study', Journal of Cancer, vol. 7, no. 2, pp. 136-143.pdf. https://doi.org/10.7150/jca.13405

Clinical practice in the use of adjuvant chemotherapy for patients with colon cancer in South Korea : A multi-center, prospective, observational study. / Kim, Jung Han; Baek, Moo Jun; Ahn, Byung Kwon; Kim, Dae Dong; Kim, Ikyong; Kim, Jin Soo; Bae, Byung Noe; Seo, Bong Gun; Jung, Sang Hun; Hong, Kwan Hee; Kim, Hungdai; Park, Dong Guk; Lee, Ji Hye.

In: Journal of Cancer, Vol. 7, No. 2, 01.01.2016, p. 136-143.pdf.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical practice in the use of adjuvant chemotherapy for patients with colon cancer in South Korea

T2 - A multi-center, prospective, observational study

AU - Kim, Jung Han

AU - Baek, Moo Jun

AU - Ahn, Byung Kwon

AU - Kim, Dae Dong

AU - Kim, Ikyong

AU - Kim, Jin Soo

AU - Bae, Byung Noe

AU - Seo, Bong Gun

AU - Jung, Sang Hun

AU - Hong, Kwan Hee

AU - Kim, Hungdai

AU - Park, Dong Guk

AU - Lee, Ji Hye

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background: Adjuvant chemotherapy is a crucial part of treatment for patients with locally advanced colon cancer. This study was conducted to investigate the actual practice in the use of adjuvant chemotherapy for patients with high-risk stage II or stage III colon cancer in South Korea. Methods: This was a 24-month open-label, prospective, observational study conducted at 12 centers across South Korea. Patients with high-risk stage II and stage III colon cancer receiving adjuvant chemotherapy after curative surgery were included, and data were collected at baseline, third, and sixth month. Results: A total of 246 patients were included in the analyses. Of five available regimens (FOLFOX, CAPOX, 5-FU/LV, capecitabine, and UFT/LV), FOLFOX was most commonly used (82.5%). Investigators indicated the "efficacy" as the major cause for selecting FOLFOX or CAPOX. For 5-FU/LV, capecitabine, or UFT/LV, the "safety" or "patient's characteristics (age, comorbidity, and stage)" was one of the most important selecting factors. Patients receiving 5-FU/LV, capecitabine, or UFT/LV had older age, worse PS and lower disease stage (stage II) than patients receiving FOLFOX or CAPOX. Hematologic toxicities were the most common cause of dose adjustment and treatment delay. Conclusions: In South Korea, FOLFOX was the most commonly used regimen for adjuvant chemotherapy and its efficacy was the main cause for selecting this regimen. Patients receiving 5-FU/LV, capecitabine, or UFT/LV had older age, worse PS and lower disease stage (stage II) than patients receiving FOLFOX or CAPOX.

AB - Background: Adjuvant chemotherapy is a crucial part of treatment for patients with locally advanced colon cancer. This study was conducted to investigate the actual practice in the use of adjuvant chemotherapy for patients with high-risk stage II or stage III colon cancer in South Korea. Methods: This was a 24-month open-label, prospective, observational study conducted at 12 centers across South Korea. Patients with high-risk stage II and stage III colon cancer receiving adjuvant chemotherapy after curative surgery were included, and data were collected at baseline, third, and sixth month. Results: A total of 246 patients were included in the analyses. Of five available regimens (FOLFOX, CAPOX, 5-FU/LV, capecitabine, and UFT/LV), FOLFOX was most commonly used (82.5%). Investigators indicated the "efficacy" as the major cause for selecting FOLFOX or CAPOX. For 5-FU/LV, capecitabine, or UFT/LV, the "safety" or "patient's characteristics (age, comorbidity, and stage)" was one of the most important selecting factors. Patients receiving 5-FU/LV, capecitabine, or UFT/LV had older age, worse PS and lower disease stage (stage II) than patients receiving FOLFOX or CAPOX. Hematologic toxicities were the most common cause of dose adjustment and treatment delay. Conclusions: In South Korea, FOLFOX was the most commonly used regimen for adjuvant chemotherapy and its efficacy was the main cause for selecting this regimen. Patients receiving 5-FU/LV, capecitabine, or UFT/LV had older age, worse PS and lower disease stage (stage II) than patients receiving FOLFOX or CAPOX.

UR - http://www.scopus.com/inward/record.url?scp=84954208782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954208782&partnerID=8YFLogxK

U2 - 10.7150/jca.13405

DO - 10.7150/jca.13405

M3 - Article

VL - 7

SP - 136-143.pdf

JO - Journal of Cancer

JF - Journal of Cancer

SN - 1837-9664

IS - 2

ER -